Hepatitis C and diabetes: The inevitable coincidence?

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 3, 2009, Pages 293-308

  Lonardo, Amedeo ^a,b,e   Adinolfi, Luigi Elio ^c   Petta, Salvatore ^d   Craxi, Antonio ^d   Loria, Paola ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b AUSL Modena   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

^e Ospedale di Baggiovara   (Italy)

Author keywords

Cirrhosis; Diabetis; Fibrosis; Hepatitis C virus; Hepatocellular carcinoma; Insulin resistance; Metabolic syndrome; Steatosis

Indexed keywords

ADIPONECTIN; GLITAZONE DERIVATIVE; INSULIN RECEPTOR SUBSTRATE 1; INTERFERON; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIVIRAL THERAPY; ARTICLE; CAUSAL ATTRIBUTION; CYTOKINE PRODUCTION; DIABETOGENESIS; DISEASE ASSOCIATION; DNA POLYMORPHISM; DOWN REGULATION; EPIDEMIOLOGICAL DATA; FATTY LIVER; GENE ACTIVATION; GENE ACTIVITY; GENE FUNCTION; GENE OVEREXPRESSION; GENOTYPE; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEPATITIS C; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; MIXED INFECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; POPULATION DISTRIBUTION; PREVALENCE; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; RISK FACTOR; SCREENING TEST; CLASSIFICATION; GENETICS; HEALTH; HEPATITIS C VIRUS; LIVER CIRRHOSIS; PATHOGENICITY; REVIEW; VIROLOGY;

DIABETES MELLITUS, TYPE 2; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; LIVER CIRRHOSIS; PREVALENCE; RISK FACTORS; WORLD HEALTH;

EID: 67649105708     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.3     Document Type: Article

References (155)

1. Naunyn B. Glykosurie und Diabetes durch experimentelle Insulite und Kankheiten der Leber. In: Der Diabetes Mellitus. Naunyn B (Ed). Nothnagel, Vienna, Austria (1906).
2. Reinberg MH, Lipson M. The association of Laennec's cirrhosis with diabetes mellitus. Ann. Intern. Med. 33(5), 1195-1202 (1950).
3. Kopetz K. The pathogenesis of hepatogenic diabetes mellitus. Klin. Wochenschr. 48(21), 1259-1265 (1970).
4. Cacciatore L, Grazia Giardina M, Cozzolino G et al. Diabetes mellitus and chronic liver disease. Gastroenterology 88(5 Pt 1), 1292. Erratum in: Gastroenterology (1985)89, 1219 (1985).
5. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J. Hepatol. 21(6), 1135-1139 (1994).
6. Giusti G, Pasquale G, Galante D et al. Clinical and histological aspects of chronic HCV infection and cirrhosis. Hepatogastroenterology 40(4), 365-369 (1993).
7. Goodman ZD, Ishak KG. Histopathology of hepatitis C virus infection. Semin. Liver Dis. 15(1), 70-81 (1995).
8. Fischer HP, Willsch E, Bierhoff E, Pfeifer U. Histopathologic findings in chronic hepatitis C. J. Hepatol. 24(2 Suppl.), 35-42 (1996).
9. Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G. Hepatitis C and steatosis: a reappraisal. J. Viral Hepat. 13(2), 73-80 (2006).
10. Lonardo A, Adinolfi LE, Loria P et al. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 126(2), 586-597 (2004).
11. Van Steenbergen W, Lanckmans S. Liver disturbances in obesity and diabetes mellitus. Int. J. Obes. Relat. Metab. Disord. 19(Suppl. 3), S27-S36 (1995).
12. Chatila R, West AB. Hepatomegaly and abnormal liver tests due to glycogenosis in adults with diabetes. Medicine (Baltimore) 75(6), 327-333 (1996).
13. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 366(9491), 1059-1062 (2005).
14. Donnelly KL, Smith CI, Schwarzenberg SJ et al. Sources of fatty acids stored in liver and secreted via lipoproreins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115(5), 1343-1351 (2005)
15. Lonardo A, Lombardini S, Scaglioni F et al. Hepatic steatosis and insulin resistance: does etiology make a difference? J. Hepatol. 44(1), 190-196 (2006).
16. Minehira K, Young SG, Villanueva CJ et al. Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice. J. Lipid Res. 49(9), 2038-2044 (2008).
17. Kantartzis K, Machicao F, Machann J et al. The DGAT2 gene is a candidate for dissociation between fatty liver and insulin resistance in humans. Clin. Sci. (Lond) 116(6), 531-517(2008).
18. Schonfeld G, Yue P, Lin X, Chen Z. Fatty liver and insulin resistance: not always linked. Trans. Am. Clin. Climatol. Assoc. 119, 217-224 (2008).
19. Mirandola S, Realdon S, Iqbal] et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 130(6), 1661-1669 (2006).
20. Zampino R, Ingrosso D, Durante-Mangoni E et al. Microsomal triglyceride transfer protein (MTP) -493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3 infected patients. J. Viral Hepat. 15(10), 740-746 (2008).
21. Hui JM, Sud A, Farrell GC et al. Insulin resistance is associated with chronic, hepatitis C virus infection and fibrosis progression. Gastroenterology 125(6), 1695-1704 (2003).
22. Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T. LIDO Study Group. Fibrogenic impact of high serum glucose in chronic hepatitis C. J. Hepatol. 39(6), 1049-1055 (2003).
23. Sud A, Hui JM, Farrell GC et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 39(5), 1239-1247 (2004).
24. D'Sbuza R, Sabin GA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am. J. Gastroenterol. 100(7), 1509-1515 (2005).
25. Muzzi A, Leandro G, Rubbia-Brandt L et al. Swiss Hepatitis C Cohort Study. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J. Hepatol. 42(1), 41-46 (2005).
26. Fartoux L, Poujol-Robert A, Guechot J et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 54(7), 1003-1008 (2005).
27. Bugianesi E, Marchesini G, Gentilcore E et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology 44(6), 1648-1655 (2006).
28. Taura N, Ichikawa T, Hamasaki K et al. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. Am. J. Gastronterol. 101(12), 2752-2759 (2006).
29. Masarone M, La Mura V, Bruno S et al. Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease. J. Viral Hepat. 14(10), 714-720 (2007).
30. Svegliati-Baroni G, Bugianesi E, Bouserhal T et al. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease. Gut 56 (9), 1296-1301 (2007).
31. Petta S, Cammà C, Marco VD et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am. J. Gastroenterol. 103(5), 1136-1144 (2008).
32. Moucari R, Asselah T, Cazals-Hatem D et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 134(2), 416-423 (2008).
33. Cua IH, Hui JM, Kench JG, George J. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 48(3), 723-731 (2008).
34. Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of Type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin. Proc. 75(4), 355-359 (2000).
35. Yokoyama H, Emoto M, Fujiwara S et al. Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment in normal range weight and moderately obese Type 2 diabetic patients. Diabetes Care 26(8), 2426-2432 (2003).
36. Wang CS, Wang ST, Yao WJ, Chang TT, Chou P. Hepatitis C virus infection and the development of Type 2 diabetes in a community-based longitudinal study. Am. J. Epidemiol. 166(2), 196-203 (2007).
37. Mehta SH, Brancati FL, Strathdee SA et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 38(1), 50-56 (2003).
38. Lecube A, Hernandez C, Genesca J et al. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury. Diabetes Care 27(11), 1171-1175 (2004).
39. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/ PI3-kinase signalling in patients with HCV: a mechanism for increased prevalence of Type 2 diabetes. Hepatology 38(6), 1384-1392 (2003).
40. Sheikh MY, Choi J, Qadri I, Friedman JE. Sanyal AJ. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology 47(6), 2127-2133 (2008).
41. Okuda M, Li K, Beard MR et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122(2), 366-375 (2002).
42. Tardif KD, Mori K, Siddiqui A. Hepatitis C virus subgenomic replicons induce endoplasmic reticulum stress activating an intracellular signaling pathway. J. Virol. 76(15), 7453-7459 (2002).
43. Thoren F, Romero A, Lindh M, Dahlgren C, Hellstrand K. A hepatitis C virus-encoded, nonstructural protein (NS3) triggers dysfunction and apoptosis in lymphocytes: role of NADPH oxidase-derived oxygen radicals. J. Leukoc. Biol. 76(6), 1180-1186 (2004).
44. Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-κ B. Proc. Natl Acad. Sci. USA 98(17), 9599-9604 (2001).
45. Hassan M, Selimovic D, Ghozlan H, Abdel-Kader O. Induction of highmolecular-weight (HMW) tumor necrosis factor (TNF) α by hepatitis C virus (HCV) non-structural protein 3 (NS3) in liver cells is AP-1 and NF-κaB-dependent activation. Cell Signal. 19(2), 301-311 (2007).
46. Knobler H, Schattner A. TNF-α, chronic hepatitis C and diabetes: a novel triad. QJM 98(1), 1-6 (2005).
47. Shintani Y, Fujie H, Miyoshi H et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 126(3), 840-848 (2004).
48. Miyamoto H, Moriishi K, Moriya K et al. Involvement of the PA28γ-dependent pathway in insulin resistance induced by hepatitis C virus core protein. J. Virol. 81(4), 1727-1735 (2007).
49. Knobler H, Zhornicky T, Sandler A et al. Tumor necrosis factor-α-Induced insulin resistance may mediate the hepatitis C virus - diabetes association. Am. J. Gastroenterol. 98(12), 2751-2756 (2003).
50. Kawaguchi T, Yoshida T, Harada M et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling. Am. J. Pathol. 165(5), 1499-1508 (2004).
51. Pazienza V, Clément S, Pugnale P et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 45(5), 1164-1171 (2007).
52. Banerjee S, Saito K, Ait-Goughoulte M et al. Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream Akt/procein kinase B signaling pathway for insulin resistance. J. Virol. 82(6), 2606-2612 (2008).
53. Bernsmeier C, Duong FH, Christen V et al. Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C. J. Hepatol. 49(3), 429-440 (2008).
54. Asselah T, Bièche, I, Laurendeau I et al. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 129(6), 2064-2075 (2005).
55. Mason AL, Lau JY, Hoang N et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29(2), 328-333 (1999).
56. Yoneda M, Saito S, Ikeda T et al. Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients. J. Viral Hepat. 14(9), 600-607 (2007).
57. Romero-Gómez M, Del Mar Viloria M, Andrade RJ et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128(3), 636-641 (2005).
58. Liu CJ, Chen PJ, Jeng YM et al. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J. Hepatol. 43(2), 235-242 (2005).
59. Siagris D, Vafiadis G, Michalaki M et al. Serum adiponectin in chronic hepatitis C and B. J. Viral Hepat. 14(8), 577-583 (2007).
60. Zografos TA, Liaskos C, Rigopoulou EI et al. Adiponectin: a new independent predictor of liver steatosis and response to IFN-α treatment in chronic hepatitis C. Am. J. Gastroenterol. 103(3), 605-614 (2008).
61. Cua IH, Hui JM, Bandara P et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 46 (1), 66-73 (2007).
62. Alter MJ. Epidemiology of hepatitis C virus infection. World J. Gastroenterol. 13(17), 2436-2441 (2007).
63. Armstrong GL, Wasley A, Simard EP et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann. Intern. Med. 144(10), 705-714 (2006).
64. Law MG, Dore GJ, Bath N et al. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int. J. Epidemiol. 32(5), 717-724 (2003).
65. Dominguez A, Bruguera M, Vidal J, Plans P, Salleras L. Community-based seroepidemiological survey of HCV infection in Catalonia, Spain. J. Med. Virol. 65(4), 688-693 (2001).
66. Sun CA, Chen HC, Lu SN et al. Persistent hyperendemicity of hepatitis C virus infection in Taiwan: the important role of iatrogenic risk factors. J. Med. Virol. 65(1), 30-34 (2001).
67. Campello C, Poli A, Dal MG, Besozzi-Valentini F. Seroprevalence, viremia and genotype distribution of hepatitis C virus: a community-based population study in northern Italy. Infection 30(1), 7-12 (2002).
68. Sagnelli E, Stroffolini T, Mele A et al. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. J. Med. Virol. 75(4), 522-527 (2005).
69. Zhang M, Sun XD, Mark SD et al. Hepatitis C virus infection, Linxian, China. Emerg. Infect. Dis. 11(1), 17-21 (2005).
70. Di Stefano R, Stroffolini T, Ferraro D et al. Endemic hepatitis C virus infection in a Sicilian town: further evidence for iatrogenic transmission. J. Med. Virol. 67(3), 339-344 (2002).
71. Maio G, d'Argenio P, Stroffolini T et al. Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a southern Italian town. J. Hepatol. 33(1), 116-120 (2000).
72. Okayama A, Stuver SO, Tabor E et al. Incident hepatitis C virus infection in a community-based population in Japan. J. Viral Hepat. 9(1), 43-51 (2002).
73. Abdel-Aziz F, Habib M, Mohamed MK et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology 32(1), 111-115 (2000).
74. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5), 1047-1053 (2004).
75. Cowie CC, Rust KF, Byrd-Holt DD et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 29(6), 1263-1268 (2006).
76. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 106(25), 3143-3421 (2002).
77. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(6), 2735-2752 (2005).
78. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 28(11), 2745-2749 (2005).
79. Miccoli R, Bianchi C, Odoguardi L et al. Prevalence of the metabolic syndrome among Italian adults according to ATP III definition. Nutr. Metab. Cardiovasc. Dis. 15(4), 250-254 (2005).
80. Athyros VG, Bouloukos VI, Pehlivanidis AN et al. The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study. Diabetes Obes. Metab. 7(4), 397-405 (2005).
81. Ferrannihi E. Metabolic syndrome: a solution in search of a problem. J. Clin. Endocrinol. Metab. 92(2), 396-398 (2007).
82. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 30(1), 8-13 (2007).
83. Weinman SA, Belalcazar LM. Hepatitis C: a metabolic liver disease. Gastroenterology 126(3), 917-919 (2004).
84. Cortez-Pinto H. Concluding remarks: metabolic syndrome, liver and HCV. Aliment. Pharmacol. Ther. 22(Suppl. 2), 83-85 (2005).
85. Koike K. Hepatitis C as a metabolic disease: implication for the pathogenesis of NASH. Hepatol. Res. 33(2), 145-150 (2005).
86. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287(3), 356-359 (2002).
87. Sanyal AJ, Contos MJ, Sterling RK et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am. J. Gastroenterol. 98(9), 2064-2071 (2003).
88. Shaheen M, Echeverry D, Oblad MG et al. Hepatitis C, metabolic syndrome, and inflammatory markers: results from the Third National Health and Nutrition Examination Survey [NHANES III]. Diabetes Res. Clin. Pract. 75(3), 320-326 (2007).
89. Hanouneh IA, Feldstein AE, Lopez R et al. Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection. Clin. Gastroenterol. Hepatol. 6(5), 584-589 (2008).
90. Persico M, Capasso M, Persico E et al. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: insulin resistance and response to antiviral therapy. Hepatology 46(4), 1009-1015 (2007).
91. Svegliati-Baroni G, Bugianesi E, Bouserhal T et al. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease. Gut 56(9), 1296-1301 (2007).
92. Targher G, Bertolini L, Padovani R et al. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J. Hepatol. 46(6), 1126-1132 (2007).
93. Lonardo A, Ballestri S, Adinolfi LE et al. HCV infected patients are "spared" from the metabolic syndrome but not from insulin resistance. A comparative study of NAFLD and HCV-related steatosis. Can. J. Gastro. 23 (2009) (In Press).
94. Tsochatzis E, Papatheodoridis GV, Manesis EK et al. Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 27(1), 80-89 (2008).
95. Chen W, Wong T, Omlinson G, Murray Krahn M, Heathcote EJ. Prevalence and predictors of obesity among individuals with positive hepatitis C antibody in a tertiary referral clinic. J. Hepatol. 49(5), 711-717 (2008).
96. Dai CY, Chuang WL, Ho CK et al. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J. Hepatol. 49(1), 9-16 (2008).
97. Poynard T, Cacoub P, Ratziu V et al. Fatigue in patients with chronic hepatitis C. J. Viral Hepat. 9(4), 295-303 (2002).
98. Lonardo A, Loria P. The hepatitis C virus-associated dysmetabolic syndrome. Hepatology 48(3), 1018-1019 (2008).
99. Lonardo A, Loria P, Carulli N. Dysmetabolic changes associated with HCV: a distinct syndrome? Intern. Emerg. Med. 3(2), 99-108 (2008).
100. Sheikh SM. The hepatitis C virus-associated dysmetabolic syndrome. Reply. Hepatology 48(3), 9 (2008).
101. Simo R, Hernandez C, Genesca J, Jardi R, Mesa J. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 19(9), 998-1000 (1996).
102. Sangiorgio L, Attardo T, Gangemi R et al. Increased frequency of HCV and HBV infection in Type 2 diabetic patients. Diabetes Res. Clin. Pract. 48(2), 147-151 (2000).
103. Okan V, Araz M, Aktaran S et al. Increased frequency of HCV but not HBV infection in Type 2 diabetic patients in Turkey. Int. J. Clin. Pract. 56(3), 175-177 (2002).
104. Arao M, Murase K, Kusakabe A et al. Prevalence of diabetes mellitus in Japanese patients infected chronically with hepatitis C virus. J. Gastroenterol. 38(4), 355-360 (2003).
105. Chen HF, Li CY, Chen P, See TT, Lee HY. Seroprevalence of hepatitis B and C in Type 2 diabetic patients. J. Chin. Med. Assoc. 69(4), 146-152 (2006).
106. Parolin MB, Réa R, Vargas RM et al. Prevalence of hepatitis C infection in patients with Type 2 diabetes mellitus. Arq. Gastroenterol. 43, 71-72 (2006).
107. Huang JF, Dai CY, Hwang SJ et al. Hepatitis C viremia increases the association with Type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Am. J. Gastroenterol. 102(6), 1237-1243 (2007).
108. Picerno I, Di Pietro A, Spataro P et al. Is diabetes mellitus a risk factor for HCV infection? Ann. Ig. 14(6), 473-477 (2002)
109. Costa LM, Mussi AD, Brianeze MR, Souto FJ. Hepatitis C as a risk factor for diabetes type 2: lack of evidence in a hospital in central-west Brazil. Braz. J. Infect. Dis. 12(1), 24-26 (2008).
110. Grimbert S, Valensi P, Levy-Marchal C et al. High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case control study. Gastroenterol. Clin. Biol. 20(6-7), 544-548 (1996).
111. El-Zayadi AR, Selim OE, Hamdy H et al. Association of chronic hepatitis C infection and diabetes mellitus. Trop. Gastroenterol. 19(4), 141-144 (1998).
112. Caronia S, Taylor K, Pagliaro L et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 30(4), 1059-1063 (1999).
113. Boschi-Pinto C, Stuver S, Okayama A et al. A follow-up study of morbidity and mortality associated with hepatitis C virus infection and its interaction with human T lymphotropic virus type I in Miyazaki, Japan. J. Infect. Dis. 181(1), 35-41 (2000).
114. Zein NN, Abdulkarim AS, Wiesner RH, Egan KS, Persing DH. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J. Hepatol. 32(2), 209-217 (2000).
115. Bigam DL, Pennington JJ, Carpentier A et al. Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. Hepatology 32(1), 87-90 (2000).
116. Qureshi H, Ahsan T, Mujeeb SA et al. Diabetes mellitus is equally frequent in chronic HCV and HBV infection. J. Pak. Med. Assoc. 52(7), 280-283 (2002).
117. Akbar DH, Siddique AM, Ahmed MM. Prevalence of Type-2 diabetes in patients with hepatitis C and B virus infection in Jeddah, Saudi Arabia. Med. Princ. Pract. 11(2), 82-85 (2002).
118. Thuluvath PJ, John PR. Association between hepatitis C, diabetes mellitus, and race. A case - control study. Am. J. Gastroenterol. 98(2), 438-441 (2003).
119. Howard AA, Klein RS, Schoenbaum EE. Association of hepatitis C infection and antiretroviral use with diabetes mellitus in drug users. Clin. Infect. Dis. 36(10), 1318-1323 (2003).
120. Antonelli A, Ferri C, Fallahi P et al. Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients. Rheumatology (Oxford) 43(2), 238-224 (2004).
121. Antonelli A, Ferri C, Failahi P et al. Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care 28, 2548-2550 (2005).
122. Papatheodoridis GV, Chrysanthos N, Savvas S et al. Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. J. Viral Hepat. 13(5), 303-310 (2006).
123. Butt AA, Evans R, Skanderson M, Shakil AO. Comorbid medical and psychiatric conditions and substance abuse in HCV infected persons on dialysis. J. Hepatol. 44(3), 864-868 (2006).
124. Marzouk D, Sass J, Bakr I et al. Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut 56(8), 1105-1110 (2007).
125. Imazeki F, Yokosuka O, Fukai K et al. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus infected and hepatitis C virus-cleared patients. Liver Int. 28(3), 355-362 (2008).
126. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J. Hepatol. 49 (5), 831-844 (2008).
127. Mehta SH, Brancati FL, Sulkowski MS et al. Prevalence of Type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann. Intern. Med. 133(8), 592-599 (2000).
128. Wang CS, Wang ST, Yao WJ, Chang TT, Chou P. Community-based study of hepatitis C virus infection and Type 2 diabetes: an association affected by age and hepatitis severity status. Am. J. Epidemiol. 158(12), 1154-1160 (2003).
129. Knobler H, Stagnaro-Green A, Wallenstein S, Schwartz M, Roman SH. Higher incidence of diabetes in liver transplant recipients with hepatitis C. J. Clin. Gastroenterol. 26(1), 30-33 (1998).
130. Baid S, Cosimi AB, Farrell ML et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 72(6), 1066-1072 (2001).
131. Khalili M, Lim JW, Bass N et al. New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl. 10(3), 349-355 (2004).
132. Delgado-Borrego A, Casson D, Schoenfeld D et al. Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation 77(5), 703-710 (2004).
133. Fabrizi F, Lampertico P, Lunghi G et al. Review article: hepatitis C virus infection and Type-2 diabetes mellitus in renal diseases and transplantation. Aliment. Pharmacol. Ther. 21(6), 623-632 (2005).
134. Butt AA, Fultz SL, Kwoh CK et al. Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection. Hepatology 40(1), 115-119 (2004).
135. Ledergerber B, Furrer H, Rickenbach M et al. Factors associated with the incidence of Type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin. Infect. Dis. 45(1), 111-119 (2007).
136. Stapleton JT, Bennett K, Bosch RJ, Polgreen PM, Swindells S. Effect of antiretroviral therapy and hepatitis C co-infection on changes in lipid levels in HIV-infected patients 48 weeks after initiation of therapy. HIV Clin. Trials 8(6), 429-436 (2007).
137. Jain MK, Aragaki C, Fischbach L et al. Hepatitis C is associated with Type 2 diabetes mellitus in HIV-infected persons without traditional risk factors. HIV Med. 8(8), 491-497 (2007).
138. Brar I, Shuter J, Thomas A, Daniels E, Absalon J. A comparison of factors associated with prevalent diabetes mellitus among HIV-infected antiretroviral-naive individuals versus individuals in the National Health and Nutritional Examination Survey cohort. J. Acq. Immun. Def. Synd. 45(1), 66-71 (2007).
139. Adinolfi LE, Gambardella M, Andreana A et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33(6), 1358-1364 (2001).
140. Asselah T, Boyer N, Guimont MC et al. Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut 52(11), 1638-1643 (2003).
141. Rubbia-Brandt L, Fabris P, Paganin S et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 53(3), 406-412 (2004).
142. Patton HM, Patel K, Behling C et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J. Hepatol. 40(3), 484-490 (2004).
143. Bianchi G, Marchesini G, Zoli M et al. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 20(1 Pt 1), 119-125 (1994).
144. Nishida T, Tsuji S, Tsujii M et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am. J. Gastroenterol. 101(1), 70-75 (2006).
145. Sigal SH, Stanca CM, Kontorinis N, Bodian C, Ryan E. Diabetes mellitus is associated with hepatic encephalopathy in patients with HCV cirrhosis. Am. J. Gastroenterol. 101(7), 1490-1496 (2006).
146. Walsh MJ, Jonsson JR, Richardson MM et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS 3) in patients with chronic hepatitis C, viral genotype 1. Gut 55(4), 529-535 (2006).
147. Kawaguchi T, Ide T, Taniguchi E et al. Clearance of HCV improves insulin resistance, β-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am. J. Gastroenterol. 102(3), 570-576 (2007).
148. Tanaka H, Shiota G, Kawasaki H. Changes in glucose tolerance after interferon-α therapy in patients with chronic hepatitis C. J. Med. 28(5-6), 335-346 (1997).
149. Simó R, Lecube A, Genescà J, Esteban JI, Hernández C. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care 29(11), 2462-2466 (2006).
150. Giordanino C, Bugianesi E, Smedile A et al. Incidence of Type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. Am. J. Gastroenterol. 103(10), 2481-2487 (2008).
151. Arase Y, Suzuki F, Suzuki Y, Akuta N et al. Sustained virological response reduces incidence of onset of Type 2 diabetes in chronic hepatitis C. Hepatology 49(3), 739-744 (2009).
152. Kwon SY, Kim SS, Kwon OS et al. Prognostic significance of glycaemic control in patients with HBV and HCV-related cirrhosis and diabetes mellitus. Diabet. Med. 22(11), 1530-1535 (2005).
153. Hickman IJ, Clouston AD, Macdonald GA et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 51(1), 89-94 (2002).
154. Lonardo A, Carulli N, Loria P. HCV and diabetes. A two-question-based reappraisal. Dig. Liver Dis. 39(8), 753-761 (2007).
155. Mangia A, Schiavone G, Lezzi G et al. HCV and diabetes mellitus: evidence for a negative association. Am. J. Gastroenterol. 93(12), 2363-2367 (1998).